FGFR1 and breast cancer: The same study also noted that combined treatment of ER+ FGFR1/CCND1 co-amplified CAMA1 BC cells with palbociclib, and/or the FGFR1 inhibitor, lucitanib, lead to a reversal in antioestrogen resistance (17).